Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript

Nov 15, 2021 / 08:00PM GMT
Release Date Price: $88.82
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm smid-cap biotech analyst at the Barclays. Welcome to our fifth gene editing and gene therapy summit. It is my great pleasure to introduce our next presenting company, Sarepta. With us, we have a Doug Ingram, President and Chief Executive Officer. We have Ian Estepan, EVP and Chief Financial Officer. We have a Louise Rodino-Klapac, EVP and the Chief Scientific Officer.

With that, I hand over to Doug to give a brief overview before we dive into the Q&A.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you very much, Gena, and thank you for having us today. So I'll try to be brief, but 2021 has been really important and pivotal year for us. In fact, as a result of the progress we've made this year and think about it, the approvals, our third approval, revenue, data, manufacturing, CMC success, regulatory success, we stand right now, I think, in the single most exciting moment in our entire

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot